Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community Where are GT20029 phase II results?

      in Research/Science  3 upvotes 2 years ago
      The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

      community Making PG free solution at home

      in Product  1 upvotes 2 years ago
      A user wants to make a solution for RU58841 and finasteride powder using only glycerin and asks if ethanol is necessary. They are seeking advice on whether glycerin alone is sufficient.

      community Can we get a reality check on PP405?

      in Research/Science  81 upvotes 8 months ago
      PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

      community I wish pp405 work and i have full head of hair in 2028-2030

      in Chat  106 upvotes 8 months ago
      People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

      community RU and cetosomal minoxidil topical

      in Minoxidil  1 upvotes 4 months ago
      Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.